英文别名:
1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-[[7-methoxy-6-[(methylamino)carbonyl]-4-quinolinyl]oxy]phenyl]-;XL092;JUN04542;NSC828252;N-(4-Fluorophenyl)-N-(4-((7-methoxy-6-(methylcarbamoyl)quinolin-4-yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide;1-N'-(4-fluorophenyl)-1-N-[4-[7-methoxy-6-(methylcarbamoyl)quinolin-4-yl]oxyphenyl]cyclopropane-1,1-;Zanzalintinib;compound 8 (WO2019148044A1);Multi-kinase Inhibitor XL092;compound 8 [WO2019148044A1];NSC-828252;US11542259, Compound 8;XL 092 [WHO-DD];CS-0167112;HY-138696;XL-092;N-(4-Fluorophenyl)-N'-(4-((7-methoxy-6- (methylcarbamoyl)quinolin-4- yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide;JUN04542?;N1-(4-fluorophenyl)-N'1-(4-{[7-methoxy-6-(methylcarbamoyl)quinolin-4-yl]oxy}phenyl)cyclopropane-1,1-dicarboxamide;1-N'-(4-fluorophenyl)-1-N- [4-[7-methoxy-6- (methylcarbamoyl)quinoln-4- yl]oxyphenyl]cyclopropane-1,1- dicarboxamide;SCHEMBL21200856;MS-29780;AKOS040759638;G17814;N-(4-fluorophenyl)-N'-(4-{[7-methoxy-6- (methylcarbamoyl)quinolin-4- yl]oxy}phenyl)cyclopropane-1,1-dicarboxamide;BDBM588214;Xl 092;ZANZALINTINIB [USAN];1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-[[7-methoxy-6-[(methylamino)carbonyl]-4-quinolinyl]oxy]phenyl]-;1-N'-(4-fluorophenyl)-1-N-(4-(7-methoxy-6-(methylcarbamoyl)quinolin-4-yl)oxyphenyl)cyclopropane-1,1-dicarboxamide;AC-36753;D12650;N-(4-Fluorophenyl)-N'-(4-((7-methoxy-6-(methylcarbamoyl)quinolin-4-yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide;Zanzalintinib (USAN/INN);1-N'-(4-fluorophenyl)-1-N-[4-[7-methoxy-6-(methylcarbamoyl)quinolin-4-yl]oxyphenyl]cyclopropane-1,1-dicarboxamide;EX-A5029;GTPL12093;KC2JC2ZA04;CHEMBL5314428;CL-092;2367004-54-2;UNII-KC2JC2ZA04;Zanzalintinib [INN];1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-(4-((7-methoxy-6-((methylamino)carbonyl)-4-quinolinyl)oxy)phenyl)-;
Inchi:
1S/C29H25FN4O5/c1-31-26(35)22-15-21-23(16-25(22)38-2)32-14-11-24(21)39-20-9-7-19(8-10-20)34-28(37)29(12-13-29)27(36)33-18-5-3-17(30)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,35)(H,33,36)(H,34,37)